Botulism Clinical Trial
Official title:
Clinical Manifestations of Botulism Outbreak in Northern Thailand: A Case Series of Botulism Treated With Botulinum Anti-Toxin.
A second botulism outbreak in Northern Thailand was reported in 2006. 192 people were
exposed to raw meat and the gut of deer, 83 suffered from diarrhea. Of these 5 developed
respiratory failure, 1 impending respiratory failure.
We analysed the clinical findings and electrophysiologic findings in this second episode of
large botulism outbreak in northern Thailand.
PRELIMINARY REPORT Northern Thailand's big botulism outbreak occurred again on 30 June 14, 2006, [16.00pm] affecting 83 from 192 people who exposed to raw dear meat and gut [1 night preserved with ice pack of whole body of dear before disection and distribution ]. Of these, 3 developed respiratory failure, 1 developed impending respiratory failure, 83 of 192 whom developed fatique and diarrhea after ingestion of raw dear meat and gut on 26-30 June 2006. 3 patients were refered to 2 high facility hospitals for severe respiratory failure. Physical examination of 3 patients in ICU of Chiang Kum general hospital revealed ptosis [3/3] mild ophthalmoparesis [2/3] Proximal muscle weakness [2/3] abdominal paradoxical respiration [3/3] pupil dilate [1/3] and negative inspiratory pressure [NIP] less than 15 mmHg [3/3] were observed. Neurological electrophysiologic study of 2 patients revealed low amplitude compound muscle action potential [CMAP] of Abductor digiti minimi [ADM] muscle with decrement response after repetitive stimulation with low frequency [3Hz], increment response of ADM muscle after stimulation with high frequency [10Hz, 20Hz, and 30Hz.].The electrophysiologic findings support diagnosis of presynaptic neuromuscular dysfunction with respiratory failure, Botulism is most likely diagnosis. After treated with botulinum antitoxin [on July,1 ,2006 [mixed-type botulinum antitoxin --donated from Japan at Nan Hospital's botulisum outbreak on March 14,2006], 3 patients in ICU showed improvement of over all clinical outcomes. Active survey by Ministry of Public Health of Thailand and CDC-USA to identify the high risk patient who may develop respiratory failure , and immunologucal vs microbiological diagnosis were performed. This outbreak may be the second hit of botulisum in the northern Thailand but less amount of severe cases was observed. ;
Observational Model: Defined Population, Time Perspective: Longitudinal
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03603665 -
A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults
|
Phase 1 | |
Not yet recruiting |
NCT04550793 -
Using Shear Wave Ultrasound Elastography for Follow up After Anti-spastic Intervention Among Stroke Patients
|
||
Completed |
NCT01441557 -
Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism
|
Phase 2/Phase 3 | |
Recruiting |
NCT05769478 -
Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA
|
Phase 1 | |
Withdrawn |
NCT01940315 -
Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B
|
Phase 3 | |
Enrolling by invitation |
NCT02051062 -
BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients
|
Phase 4 | |
Completed |
NCT02055183 -
BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin
|
||
Completed |
NCT01357213 -
Phase 1 PK Study of XOMA 3AB
|
Phase 1 | |
Completed |
NCT03676634 -
Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®
|
Phase 2 | |
Completed |
NCT00314080 -
Treatment of Survivors After Botulism Outbreak
|
N/A | |
Not yet recruiting |
NCT06112834 -
Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®
|
Phase 2 | |
Completed |
NCT00004401 -
Study of Human Botulism Immunoglobulin in Infants With Botulism
|
N/A | |
Completed |
NCT01701999 -
Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid
|
Phase 2 | |
Completed |
NCT02779140 -
Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632
|
Phase 1 |